ClinicalTrials.gg
RecruitingNCT06253429Updated Feb 12, 2024

Alpha-lipoic Acid in Diabetic Nephropathy

A Phase 3 interventional study of Thioctic Acid 333 MG Oral Capsule and Captopril 25Mg Tab in Type 1 Diabetes, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-02-12.

Sponsored by Ain Shams University · Phase 3, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Jan 2023, registered Jan 2024).
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Diabetes Mellitus, Type 1 by Ain Shams University — 3 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · Ain Shams University.

Planned enrollment
15th of 18
30 · median 60
Started
2023
the only one that year
Phase 3
3 of 20
1 open now
Registered
13th of 20
by date

Among the 20 studies in Diabetes Mellitus, Type 1 by Ain Shams University, this one is the 15th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2023, is one of 3 in phase 3, and was the 13th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 20 studies in Diabetes Mellitus, Type 1 by Ain Shams University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Diabetes Mellitus, Type 1 by Ain Shams University, or all of them as a file.
02

Study summary

Endothelial dysfunction in diabetes is a central event in the pathogenesis of different microangioapthic changes. Nephropathy in patients with type 1 diabetes is a severe microvascular complication.

Read the detailed description

Better understanding of the pathogenesis of microvascular complications in type 1 diabetes have paved the way for novel therapeutic targets and possible adjuvant therapeutic modalities. Oxidative stress is considered a common and important factor that links hyperglycemia with the vascular complications in diabetes, including of diabetic nephropathy (DN).

Alpha lipoic acid (ALA), or thioctacid, is an antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes. ALA can scavenge free radicals, activate antioxidant systems, and also affect inflammatory markers. It also has unique characteristic. ALA can play as a reduction for oxidized forms of components with antioxidant properties and neutralize reactive oxygen species. Thus, it called as antioxidant of antioxidants

03

Conditions studied

  • Type 1 Diabetes
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adolescents with type 1 diabetes
  • The presence of diabetic nephropathy

Exclusion criteria

Exclusion Criteria:

  • Renal impairment due to causes other than diabetes
  • Other diabetic complications than nephropathy
  • Elevated liver enzymes
  • to lipoic acid
  • Participation in a previous drug study within the 30 days preceding screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Interventional arm

    including pediatric patients with diabetic nephropathy receiving oral alpha-lipoic acid daily. The capsule of ALA ( Thiotex 300 mg capsule) contains 300 mg of thioctic acid, manufactured bt Marcyrl Pharmaceutical Industries - Egypt.) The patient will receive 1 capsule twice daily for 3 months. Patients' compliance to therapy will be checked by counting pills. oral angiotensin-converting enzyme inhibitors (ACE-Is) captopril 25 mg tablet provided their blood pressure will be maintained within normal range for age

    Drug: Thioctic Acid 333 MG Oral Capsule · Drug: Captopril 25Mg Tab

  • Placebo comparator
    Control Arm

    including pediatric patients with diabetic nephropathy receiving placebo that is similar in appearance to the oral alpha-lipoic acid (Thiotex 300 mg capsule) and oral angiotensin-converting enzyme inhibitors (ACE-Is)(Captopril 25 mg tablet) provided their blood pressure will be maintained within normal range for age

    Drug: Captopril 25Mg Tab

Interventions

  • DrugThioctic AcidStudies of Thioctic AcidThioctic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes

    Also known as: Alpha lipoic acid 300 mg tablet

  • DrugCaptoprilStudies of CaptoprilCaptopril pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral angiotensin-converting enzyme inhibitors

    Also known as: Capoten 25 mg tab

06

What researchers measure

Primary outcomes

  1. Changes in Total antioxidant capacity and Malondialdehyde

    Changes in Total antioxidant capacity and Malondialdehyde

    Time frame: 3 months

  2. Changes in urinary albumin excretion rate

    Changes in urinary albumin excretion rate and HbA1c

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Pediatrics and Adolescents Diabetes Unit (PADU), Pediatrics Hospital, Faculty of Medicine, Ain Shams University
    Cairo, 11765, Egypt
    Recruiting
    • Yasmine Ehenawyl · Contact+201006714334
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2024, 12 months after the start.

Of 108 phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Feb 12, 2024
StartActual
Jan 1, 2023
Primary completionEst.
Jan 31, 2024
CompletionEst.
Feb 1, 2024
Last update
Feb 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06253429
Responsible party
Sponsor
First posted
Feb 12, 2024
Start date
Jan 1, 2023
Primary completion
Jan 31, 2024 (estimated)
Completion
Feb 1, 2024 (estimated)
Last update
Feb 12, 2024

Study contacts

Yasmine I Elhenawy
Contact
dr_yasmi@yahoo.com
01006714334
Shymaa El-Morsy
Contact
01275207244
Yasmine I Elhenawy
principal investigator · Ain Shams University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thioctic Acid

Start the discussion